Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luis Dabul

Psychiatry Miami, FL Medical Doctor

NPI 1598127086 CMS profile 5704129

4030 Sw 107Th Ct, Miami, FL 33165

Open in the dashboard

General payments

$4,808

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luis Dabul of Miami, FL is reported in the CMS Open Payments database as having received $4,808 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $130 5
2024 General $2,568 108
2023 General $573 29
2022 General $798 42
2021 General $182 9
2019 General $558 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Dabul
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Luis Dabul were reported at $130. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Luis Dabul Psychiatry median Middle half National median
2019 $558 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $182 $143 $43–$576 $132
2022 $798 $153 $50–$590 $149
2023 $573 $170 $56–$651 $160
2024 $2,568 $179 $57–$673 $164
2025 $130 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $838 44 payments
  2. Teva Pharmaceuticals USA, Inc. $776 30 payments
  3. Otsuka America Pharmaceutical, Inc. $644 27 payments
  4. Janssen Pharmaceuticals, Inc $419 19 payments
  5. Lundbeck LLC $287 10 payments
  6. ITI, Inc. $285 12 payments
  7. AbbVie, Inc. $280 16 payments
  8. Almatica Pharma LLC $215 9 payments
  9. Allergan Inc. $178 13 payments
  10. Neurocrine Biosciences, Inc. $177 6 payments
  11. Other $709 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,808 217 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $570 30 payments
  2. ARISTADA Cns $570 30 payments
  3. LYBALVI $542 29 payments
  4. INVEGA SUSTENNA $419 19 payments
  5. AUSTEDO $380 11 payments
  6. ARISTADA Cns $351 17 payments
  7. ARISTADA Cns $351 17 payments
  8. ABILIFY MAINTENA $312 11 payments
  9. Austedo XR $291 13 payments
  10. REXULTI $287 10 payments
  11. Other $3,371 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,655

Median for Psychiatry: 574

Drug cost

$221,093

Median for Psychiatry: $27,624

Branded share of claims

15.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 24 $69,836
Abilify Maintena Aripiprazole Brand 27 $64,441
Abilify Asimtufii Aripiprazole Brand 13 $54,220
Trintellix Vortioxetine Hydrobromide Brand 17 $10,931
Aripiprazole Generic 63 $5,279
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 12 $2,897
Quetiapine Fumarate Generic 104 $1,565
Mirtazapine Generic 84 $939
Quetiapine Fumarate Er Quetiapine Fumarate Brand 19 $742
Hydroxyzine Pamoate Generic 87 $710

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $287
  • Otsuka America Pharmaceutical, Inc. $173
$460 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $291
$291 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $198
$198 13 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $194
$194 24 —
LOREEV XR
  • Almatica Pharma LLC $185
$185 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record